Carisma Therapeutics Inc
CARM
Get informed when a big investor buys or sells
+ FollowMarket Cap$230.15K
Close$
$-0.29
5688.5% downside
Current Fair Value
5688.5% downsideOvervalued by 5688.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $230,148.00 |
|---|---|
| Enterprise Value | $-1,784,852.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.46 |
| Beta | -9.34 |
| Outstanding Shares | 41,788,096 |
Return
| Return on Equity | -927.57% |
|---|---|
| Return on Assets | 122.70% |
| Return on Invested Capital | -8119.38% |
Valuation & Multiples
| P/E Ratio | 0.01 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.01 |
| Enterprise Value to Revenue | -0.49 |
| Enterprise Value to EBIT | -0.09 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | -0.43 |
| Debt to Equity | -0.88 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 29, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
$3.77 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.53%▼ 0.22% |
|---|---|
| Total Invested | $47,908▼ 28.46% |
| Investors Holding | 3▼ 4.00% |
ESG Score
No data
About Carisma Therapeutics Inc
35 employees
CEO: Thomas Cannell Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company's lead program, Vicineum™, also known as VB4-845, is currently in the follow-up stage ...